Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 3, 2009, Pages 981-985

  Sparks, Steven M ^a   Banker, Pierette ^a   Bickett, David M ^a   Clancy, Daphne C ^a   Dickerson, Scott H ^a   Garrido, Dulce M ^a   Golden, Pamela L ^a   Peat, Andrew J ^a   Sheckler, Lauren R ^a   Tavares, Francis X ^a   Thomson, Stephen A ^a   Weiel, James E ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Glycogen phosphorylase; Type 2 diabetes

Indexed keywords

2 AMINOBENZAMIDE; AMINO ACID; CYTOCHROME P450; GLYCOGEN PHOSPHORYLASE; SERINE; THREONINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INHIBITION; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT;

ANIMALS; ANTHRANILIC ACIDS; ARYL HYDROCARBON HYDROXYLASES; CHEMISTRY, PHARMACEUTICAL; CRYSTALLOGRAPHY, X-RAY; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; GLYCINE; GLYCOGEN PHOSPHORYLASE; HUMANS; IMIDES; INHIBITORY CONCENTRATION 50; LIVER; MODELS, CHEMICAL; RATS; SERINE; THREONINE;

EID: 58549102900     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.11.084     Document Type: Article

References (21)

1. Staehr P., Hother-Nielsen O., and Beck-Nielsen H. Diabetes Obes. Metab. 4 (2002) 215
2. Link J.T. Curr. Opin. Investig. Drugs 4 (2003) 421
3. For reviews see:. Kurukulasuriya R., Link J.T., Madar D.J., Pei Z., Rohde J.J., Richards S.J., Souers A.J., and Szczepankiewicz B.G. Curr. Med. Chem. 10 (2003) 99
4. Kurukulasuriya R., Link J.T., Madar D.J., Pei Z., Richards S.J., Rohde J.J., Souers A.J., and Szczepankiewicz B.G. Curr. Med. Chem. 10 (2003) 123
5. Kurukulasuriya R., and Link J.T. Expert Opin. Ther. Patents 15 (2005) 1739
6. Parker J.C. Drugs Fut 26 (2001) 687
7. van Poelje P.D., Dang Q., and Erion M.D. Curr. Opin. Drug Discov. Dev. 10 (2007) 430
8. Henke B.R., and Sparks S.M. Mini Rev. Med. Chem. 6 (2006) 845
9. Treadway J.L., Mendys P., and Hoover D.J. Exp. Opin. Invest. Drugs 10 (2001) 439
10. Wiedeman P.E. Prog. Med. Chem. 45 (2007) 63
11. Mayers R.M., Butlin R.J., Kilgour E., Leighton B., Martin D., Myatt J., Orme J.P., and Holloway B.R. Biochem. Soc. Trans. 31 (2003) 1165
12. Coghlan M., and Leighton B. Exp. Opin. Invest. Drugs 17 (2008) 145
13. Mohler M.L., He Y., Wu Z., Hong S.-S., and Miller D.D. Expert Opin. Ther. Patents 17 (2007) 59
14. Sparks S.M., Banker P., Bickett M., Clancy D., Dickerson S., Dvornik K., Garrido D., Golden P., Nolte R., Peat A., Sheckler L., Thomson S.A., Tavares F., Wang L., and Weiel J. Bioorg. Med. Chem. Lett. 19 (2009) 976
15. Evans K.A., Li Y.H., Coppo F.T., Graybill T.L., Cichy-Knight M., Gale J., Thrall S.H., Tew D., Tavares F., Thomson S.A., Weiel J.E., Boucheron J.A., Clancy D.C., Epperly A.H., and Golden P.L. Bioorg. Med. Chem. Lett. 18 (2008) 4068
16. Schmidt U., Lieberknecht A., Schanbacher U., Beuttler T., and Wild J. Angew. Chem. Int. Ed. Engl. 21 (1982) 776
17. Nakajima K., Takai F., Tanaka T., and Okawa K. Bull. Chem. Soc. Jpn. 51 (1978) 1577
18. Groth U., Schöllkopf U., and Tiller T. Tetrahedron 47 (1991) 2842
19. Schöllkopf U. Tetrahedron 39 (1983) 2085
20. For further experimental details, see: Evans, K. A.; Cichy-Knight, M.; Coppo, F. T.; Dwornik, K. A.; Gale, J. P.; Garrido, D. M.; Li, Y. H.; Patel, M.; Tavares, F. X.; Thomson, S. A.; Dickerson, S. H.; Peat, A. J.; Sparks, S. M.; Banker, P.; Cooper, J. P. WO 2006/052722 A1, 2006.
21. Gleeson M.P. J. Med. Chem. 51 (2008) 817